UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow

Vaccine, 2018-02, Vol.36 (9), p.1136-1145

2018

Volltextzugriff (PDF)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

PloS one, 2018-12, Vol.13 (12), p.e0208328-e0208328

2018

Volltextzugriff (PDF)

Editorial: A Global Perspective on Vaccines: Priorities, Challenges and Online Information

Frontiers in immunology, 2019-11, Vol.10, p.2556-2556

2019

Volltextzugriff (PDF)

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

Frontiers in immunology, 2022-08, Vol.13, p.978591-978591

2022

Volltextzugriff (PDF)

Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses

npj vaccines, 2021-04, Vol.6 (1), p.55-55, Article 55

2021

Volltextzugriff (PDF)

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

Frontiers in immunology, 2023-10, Vol.14, p.1267372-1267372

2023

Volltextzugriff (PDF)

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

PloS one, 2015-04, Vol.10 (4), p.e0117820-e0117820

2015

Volltextzugriff (PDF)

Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development

npj vaccines, 2018-07, Vol.3 (1), p.28-28, Article 28

2018

Volltextzugriff (PDF)

African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination

Frontiers in cellular and infection microbiology, 2022-12, Vol.12, p.1058081-1058081

2022

Volltextzugriff (PDF)

Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project

Vaccine, 2016-11, Vol.34 (48), p.5845-5854

2016

Volltextzugriff (PDF)

Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC

EBioMedicine, 2019-04, Vol.42, p.145-156

2019

Volltextzugriff (PDF)

Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen

Infection and Immunity, 2005-12, Vol.73 (12), p.8017-8026

2005

Volltextzugriff (PDF)

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults

PloS one, 2012-06, Vol.7 (6), p.e38898-e38898

2012

Volltextzugriff (PDF)

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

Vaccine, 2010-09, Vol.28 (41), p.6698-6703

2010

Volltextzugriff (PDF)

Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants

Infection and Immunity, 1998-05, Vol.66 (5), p.2093-2098

1998

Volltextzugriff (PDF)

Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

PloS one, 2015-09, Vol.10 (9), p.e0137816-e0137816

2015

Volltextzugriff (PDF)

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris

Vaccine, 2008-11, Vol.26 (48), p.6143-6150

2008

Volltextzugriff (PDF)

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

Vaccine, 2007-03, Vol.25 (14), p.2723-2732

2007

Volltextzugriff (PDF)

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

The Lancet infectious diseases, 2020-05, Vol.20 (5), p.585-597

2020

Volltextzugriff (PDF)

Malaria vaccines – how and when to proceed?

Trends in parasitology, 2009-12, Vol.25 (12), p.535-537

2009

Volltextzugriff (PDF)

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

PLoS medicine, 2017-11, Vol.14 (11), p.e1002455

2017

Volltextzugriff (PDF)

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Clinical infectious diseases, 2019-10, Vol.69 (9), p.1509-1516

2019

Volltextzugriff (PDF)

Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?

Malaria journal, 2011-09, Vol.10 (1), p.255-255, Article 255

2011

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(158)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(164)
Französisch
(13)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Editorial: A Global Perspective on Vaccines: Priorities, Challenges and Online Information

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses

Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development

African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination

Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project

Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC

Phase I Malaria Vaccine Trial with a Long Synthetic Peptide Derived from the Merozoite Surface Protein 3 Antigen

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02

Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants

Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Malaria vaccines – how and when to proceed?

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria

Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?

Suchergebnisse filtern